Novo, Sanofi and Merck & Co all scored exits as the cancer drug developer, which had been spun off by Biox Biosciences, floated in a $101m offering.

The tissue analysis device maker, a spinout from Stanford University, has selected the Nasdaq Global Select Market for its initial public offering.

SoftBank-backed co-working space provider WeWork will finally get a public listing, at a $9bn initial enterprise value.

The Alphabet and Tencent-backed automation software producer, valued at $35bn as of last month, has filed for a $1bn offering.

The Novo-backed musculoskeletal disease therapy developer floated in an upsized IPO before its share price almost doubled on its first day of trading.

Bristol Myers Squibb has scored an exit from oncology therapy deveoper Ikena, whose share priced doubled on its first day of trading.

Rock Solid Technologies is purchasing the meeting management platform developer in a deal allowing Propylon to exit.

The supply chain financing platform has filed to raise up to $1.06bn in a Hong Kong Stock Exchange offering which will enable Bertelsmann, GLP, Skyworth and Tencent to exit.

The online question-and-answer platform developer is going public alongside a $250m private placement featuring JD.com, Alibaba, Tencent and Lilith Games.

Hanwha and SoftBank could exit the advanced biomaterials developer in the offering, which will follow more than $870m in funding.